Health Screening Nz Limited

What Health Screening Nz Limited does

Health Screening NZ Limited (HSNZ) is a privately held New Zealand company founded in 2020 by pharmacist Carolyn Oakley-Brown and operating from Christchurch. The company delivers the CardiAction Heart & Artery Screening service, a non-invasive 20-minute cardiovascular risk assessment based on Pulse Wave Analysis (PWA) using the FDA/TGA-approved Uscom BP+ device. The screening measures central aortic blood pressure, arterial stiffness, augmentation index, and Subendocardial Viability Ratio (SEVR), producing a personalised CardiAction Risk Indicator score plus lifestyle and nutrition recommendations, with results delivered immediately and stored on the CardiAction cloud platform hosted on AWS in Australia.

The business operates a B2B2C distribution model. It partners with community pharmacies — including Green Cross Health and independent pharmacies nationwide — that host popup CardiAction clinics on-site at no cost to the pharmacy, with HSNZ providing screeners, equipment, and marketing and earning per-booking commission alongside driving supplementary supplement sales. The service is also sold directly to consumers via the healthscreeningnz.com website and CardiAction mobile app at NZ$119 per screening, and packaged for corporate wellness programmes (employers of all sizes) and community groups (sports clubs, gyms, churches) with group discounts at 10+ attendees. A flagship partnership with nib health insurance gives members a $15 discount and integration through the mynib app, with potential claim eligibility under policy benefits.

HSNZ operates as a licensed operator of the CardiAction technology platform owned by 3P Healthcare Pty Ltd (Australia), with the underlying hardware supplied by Uscom and cloud infrastructure by AWS. Revenue streams include individual screening fees, pharmacy commissions, corporate wellness contracts, community group packages, and insurance-driven referral volume. The company is founder-controlled, privately held, and reports headcount of 1-10 employees with no disclosed institutional funding.

Name

Health Screening Nz Limited

Legal name

Health Screening NZ Ltd

Website

https://healthscreeningnz.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Health Screening NZ is a Christchurch-based private company that delivers the CardiAction cardiovascular screening service through community pharmacies, employers, and insurers across New Zealand using Uscom BP+ Pulse Wave Analysis technology licensed from 3P Healthcare.

Ownership category

akta.pro rank

Product category

Preventive Cardiovascular Screening Services

NAICS

All Other Outpatient Care Centers (621498), Medical and Diagnostic Laboratories (62151)

SIC

Services-Health Services (8000), Services-Medical Laboratories (8071)

akta.pro primary industry

Cardiac Diagnostic Centers (Echo/Stress Testing/Holter) (HLAFAKAE)

akta.pro secondary industry

Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT) (HLAHAFAI)

Keywords

• Cardiovascular screening services
• Pulse wave analysis
• Preventive heart screening
• Community pharmacy screenings
• Workplace wellness screening

Headquarters

HQ city

Christchurch

HQ country

New Zealand

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain, Infrastructure

Revenue model

1. Individual Screening Fees: Consumers pay $119 per CardiAction Heart & Artery Screening at partner pharmacies or company-run events. This is a one-time, per-appointment fee covering the 20-30 minute PWA test, results explanation, and written report.
2. Pharmacy Partnership / Commission: Partner pharmacies host screenings with no cost to the pharmacy; Health Screening NZ earns commission per booked appointment while also driving supplementary product sales (supplements) at the pharmacy.
3. Corporate / Employer Screening Packages: Businesses purchase tailored corporate wellness screening packages for employees, with flexible payment options including full payment or subsidised employee screenings. Group discounts are available for 10 or more employees.
4. Community Group Screening Packages: Community organisations (sports clubs, gyms, churches, etc.) purchase discounted private screening packages for groups of 10 or more members, with customised scheduling and branded booking portals.
5. Insurance Partner Discounts & Referrals: nib insurance members receive a $15 discount per screening, driving volume through the nib channel. nib may also support claims processing for policyholders with relevant screening benefits.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels8 records

Core offering

Health Screening NZ delivers the CardiAction Heart & Artery Screening Service, a 20-minute non-invasive cardiovascular risk assessment performed by trained screeners using Pulse Wave Analysis (PWA) via the Uscom BP+ device. Screenings are delivered primarily through a nationwide community pharmacy network and corporate wellness deployments, producing a personalised CardiAction Risk Indicator score, immediate results, and tailored lifestyle recommendations.

Product overview

Health Screening NZ offers a single unified product—the CardiAction Heart & Artery Screening Service—which combines the Uscom BP+ hardware device with the CardiAction software platform. The service performs non-invasive Pulse Wave Analysis to measure arterial stiffness, central blood pressure, cardiac efficiency, and other cardiovascular biomarkers. Screening results are delivered immediately and transmitted to the CardiAction platform for storage; clients may optionally access results via the CardiAction mobile app. The company also offers supplementary dry-blood spot testing kits and CardiAction supplements as add-on products.

Differentiator

Problem solved

Functional benefit

Brands

• CardiAction: Heart and artery screening service using Pulse Wave Analysis technology and the Uscom BP+ machine to identify early signs of cardiovascular disease risk.

Products and services

• CardiAction Heart & Artery Screening Service A non-invasive cardiovascular screening using Pulse Wave Analysis with the Uscom BP+ device to measure central aortic blood pressure, arterial stiffness, cardiac efficiency, and vascular health. Delivered as a 20-30 minute appointment at partner pharmacies, employer workplaces, and community venues, producing a personalised CardiAction Risk Indicator score, immediate results, screener consultation, and an emailed written report with tailored lifestyle recommendations.
• Corporate / Employer Wellness Screening Packages Tailored corporate wellness packages for businesses of all sizes providing employee cardiovascular health screenings, with options for on-site deployment at workplaces or attendance at partner pharmacy locations. Includes flexible payment (full employer payment or subsidised), group discounts for 10+ employees, and branded booking portals.
• Community Group Screening Packages Discounted private screening packages for community organisations (sports clubs, gyms, churches, golf clubs, gardening clubs) for groups of 10 or more members, with customised appointment scheduling at the group's location or a partner pharmacy, personalised branded booking portals, and community discount codes.

Quantifiable outcome

• Blood pressure reduction of up to 22% achievable within 3 months through lifestyle changes identified by screening
• +4 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

Five partnerships are on record, tiered core and flagship.

• 3P Healthcare Pty LtdcoreOEM/ Whitelabel/ Licensing Partner3P Healthcare Pty Ltd (an Australian company) is the licensor of the CardiAction product, platform, and algorithm used by Health Screening NZ. Dr Paul Beaver is the Founder and Scientific Director of 3P Healthcare and led the 10-year research and development behind CardiAction. Health Screening NZ operates as a licensed operator of CardiAction technology in New Zealand. 3P Healthcare acts as a data processor for health data stored on the CardiAction platform.
• UscomcoreTechnology or IntegrationUscom is the manufacturer of the BP+ device, a TGA/FDA-approved Pulse Wave Analysis (PWA) machine used in all CardiAction screenings. The BP+ is a supra-systolic oscillometric device that measures central aortic blood pressure and arterial waveforms non-invasively. Health Screening NZ uses the BP+ as the core measurement hardware in its screening service.
• nib health insuranceflagshipGTM or Marketing Partnernib health insurance is Health Screening NZ's preferred heart health provider partner. nib members receive $15 off CardiAction Heart & Artery Screenings at eligible partner pharmacies across New Zealand. nib promotes the service through its mynib app and marketing channels. Policyholders may also be able to claim screening costs under applicable health insurance benefits.
• Green Cross Health PharmaciesflagshipChannel Partner/ Reseller/ DistributorGreen Cross Health (GXH) is a major pharmacy chain in New Zealand. Health Screening NZ partners with GXH pharmacies to host CardiAction popup screening clinics nationwide. Each clinic accommodates up to 22 appointments daily. The partnership supports GXH's 'Care + Advice' model, brings new customers to pharmacies, and generates additional revenue from supplement sales. HSNZ provides the screener, equipment, appointments, and marketing at no cost to the pharmacy, earning commission per booking.
• Amazon Web Services (AWS)coreTechnology or IntegrationAWS provides cloud infrastructure hosting for the CardiAction platform and associated health data storage in Australia. AWS adheres to robust security measures to protect personal and health information, in compliance with New Zealand and Australian data protection standards.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Cleveland HeartLab (Quest Diagnostics): Cleveland HeartLab, now part of Quest Diagnostics, offers specialised cardiovascular disease risk assessment testing (biomarkers, advanced lipid panels) through clinical channels. Comparable service category — cardiovascular risk screening — at much larger US scale via the Quest Diagnostics laboratory network.
• iRhythm Technologies: iRhythm Technologies (NASDAQ: IRTC) provides the Zio long-term cardiac monitoring service for arrhythmia detection. A broader incumbent in non-invasive / wearable cardiac diagnostic services, operating at significant scale in the US and selected international markets.
• Omron Healthcare: Omron Healthcare is a global leader in home blood pressure monitoring and connected cardiovascular health devices, including cuff-based BP monitors with central pressure measurement features. Comparable positioning in non-invasive cardiac risk monitoring at consumer and clinical scale.
• HeartFlow: HeartFlow is a US-based non-invasive cardiovascular diagnostics company offering computed tomography-derived fractional flow reserve (FFR-CT) for coronary disease assessment. A broader incumbent in non-invasive cardiac diagnostics; comparable category but different modality and substantially larger scale.

Emerging players

• Cardihab: Cardihab (Australia) provides digital cardiac rehabilitation and remote patient monitoring for heart disease patients, complementing the screening-to-rehab continuum. An adjacent emerging player in non-invasive cardiac care delivery across Australia and New Zealand.
• Withings: Withings (formerly Nokia Health) develops connected consumer health devices including blood pressure monitors, hybrid smartwatches with ECG, and a cardiovascular risk assessment platform. Comparable in delivering cardiac risk insights in non-clinical consumer settings, though via owned hardware rather than service-based screening.

Regional players

• Southern Cross Health Society: Southern Cross is New Zealand's largest health insurer, comparable to nib (HSNZ's insurance partner) in addressing the same insurer-funded preventive cardiac screening market. It represents both a potential partnership expansion target and a competitor for insurer-driven screening channels in NZ.

Others

• 3P Healthcare Pty Ltd (CardiAction): 3P Healthcare Pty Ltd is the Australian developer of the CardiAction platform and algorithm licensed by Health Screening NZ. A core enablement partner that owns the underlying screening technology and 10-year research programme underpinning the service.
• Uscom Limited: Uscom Limited (ASX: UCM) manufactures the BP+ supra-systolic oscillometric Pulse Wave Analysis device used in every CardiAction screening. Direct technology supplier to Health Screening NZ and one of the few vendors of FDA/TGA-approved non-invasive central blood pressure hardware globally.

Direct peers

• Life Line Screening: Life Line Screening operates a large community-based preventive health screening service in the US, offering cardiovascular and other screenings in convenient retail/community settings on a pay-per-screening basis. The direct analogue to Health Screening NZ's pharmacy-based CardiAction screening business model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/HealthScreeningNZ
• LinkedInlinkedin.com/company/healthscreeningnz

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Health Screening Nz Limited